{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T22:20:16Z","timestamp":1792016416074,"version":"4.4.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T00:00:00Z","timestamp":1755475200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301249"],"award-info":[{"award-number":["82301249"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2024A1515010338"],"award-info":[{"award-number":["2024A1515010338"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Projects in Guangzhou","award":["3030901006202"],"award-info":[{"award-number":["3030901006202"]}]},{"name":"Fundamental Research Funds of the State Key Laboratory of Ophthalmology","award":["83000-32030003"],"award-info":[{"award-number":["83000-32030003"]}]},{"name":"Lumitin Vision to Brightness Research Funding for the Young and middle-aged Ophthalmologists and the Global STEM Professorship Scheme","award":["P0046113"],"award-info":[{"award-number":["P0046113"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Diabetol"],"DOI":"10.1186\/s12933-025-02899-y","type":"journal-article","created":{"date-parts":[[2025,8,18]],"date-time":"2025-08-18T12:10:36Z","timestamp":1755519036000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Unveiling biomarkers via plasma metabolome profiling for diabetic macrovascular and microvascular complications"],"prefix":"10.1186","volume":"24","author":[{"given":"Zhixi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhan","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingfeng","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingguang","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,18]]},"reference":[{"issue":"2","key":"2899_CR1","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1038\/nrendo.2017.151","volume":"14","author":"Y Zheng","year":"2018","unstructured":"Zheng Y, Ley SH, Hu FB. Global aetiology and epidemiology of type 2 diabetes mellitus and its complications. Nat Rev Endocrinol. 2018;14(2):88\u201398.","journal-title":"Nat Rev Endocrinol"},{"key":"2899_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","volume":"138","author":"NH Cho","year":"2018","unstructured":"Cho NH, Shaw JE, Karuranga S, Huang Y, da Rocha Fernandes JD, Ohlrogge AW, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045. Diabetes Res Clin Pract. 2018;138:271\u201381.","journal-title":"Diabetes Res Clin Pract"},{"issue":"1","key":"2899_CR3","first-page":"21","volume":"6","author":"E Kaplovitch","year":"2021","unstructured":"Kaplovitch E, Eikelboom JW, Dyal L, Aboyans V, Abola MT, Verhamme P, et al. Rivaroxaban and aspirin in patients with symptomatic lower extremity peripheral artery disease: a subanalysis of the COMPASS randomized clinical trial. JAMA Cardiol. 2021;6(1):21\u20139.","journal-title":"JAMA Cardiol"},{"issue":"7","key":"2899_CR4","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1038\/s41581-020-0278-5","volume":"16","author":"JB Cole","year":"2020","unstructured":"Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16(7):377\u201390.","journal-title":"Nat Rev Nephrol"},{"key":"2899_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2020.108231","volume":"165","author":"CI Li","year":"2020","unstructured":"Li CI, Lin CC, Cheng HM, Liu CS, Lin CH, Lin WY, et al. Derivation and validation of a clinical prediction model for assessing the risk of lower extremity amputation in patients with type 2 diabetes. Diabetes Res Clin Pract. 2020;165: 108231.","journal-title":"Diabetes Res Clin Pract"},{"issue":"6","key":"2899_CR6","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1016\/j.neuron.2017.02.005","volume":"93","author":"EL Feldman","year":"2017","unstructured":"Feldman EL, Nave KA, Jensen TS, Bennett DLH. New horizons in diabetic neuropathy: mechanisms, bioenergetics, and pain. Neuron. 2017;93(6):1296\u2013313.","journal-title":"Neuron"},{"issue":"7946","key":"2899_CR7","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41586-022-05637-6","volume":"614","author":"MK Handzlik","year":"2023","unstructured":"Handzlik MK, Gengatharan JM, Frizzi KE, McGregor GH, Martino C, Rahman G, et al. Insulin-regulated serine and lipid metabolism drive peripheral neuropathy. Nature. 2023;614(7946):118\u201324.","journal-title":"Nature"},{"issue":"1","key":"2899_CR8","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1046\/j.1523-1755.2003.00712.x","volume":"63","author":"AI Adler","year":"2003","unstructured":"Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney Int. 2003;63(1):225\u201332.","journal-title":"Kidney Int"},{"issue":"7","key":"2899_CR9","doi-asserted-by":"publisher","first-page":"1834","DOI":"10.2337\/dc07-0019","volume":"30","author":"K Krzyzanowska","year":"2007","unstructured":"Krzyzanowska K, Mittermayer F, Wolzt M, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2007;30(7):1834\u20139.","journal-title":"Diabetes Care"},{"key":"2899_CR10","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa188","author":"M Croyal","year":"2020","unstructured":"Croyal M, Saulnier PJ, Aguesse A, Gand E, Ragot S, Roussel R, et al. Plasma trimethylamine N-oxide and risk of cardiovascular events in patients with type 2 diabetes. J Clin Endocrinol Metab. 2020. https:\/\/doi.org\/10.1210\/clinem\/dgaa188.","journal-title":"J Clin Endocrinol Metab"},{"key":"2899_CR11","unstructured":"SCORE2-Diabetes: 10-year cardiovascular risk estimation in type 2 diabetes in Europe. Eur Heart J. 2023;44(28):2544\u201356."},{"key":"2899_CR12","doi-asserted-by":"publisher","DOI":"10.3390\/cells10112832","author":"Q Jin","year":"2021","unstructured":"Jin Q, Ma RCW. Metabolomics in diabetes and diabetic complications: insights from epidemiological studies. Cells. 2021. https:\/\/doi.org\/10.3390\/cells10112832.","journal-title":"Cells"},{"issue":"5","key":"2899_CR13","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1016\/j.cell.2020.07.040","volume":"182","author":"JM Wozniak","year":"2020","unstructured":"Wozniak JM, Mills RH, Olson J, Caldera JR, Sepich-Poore GD, Carrillo-Terrazas M, et al. Mortality Risk Profiling of Staphylococcus aureus Bacteremia by Multi-omic Serum Analysis Reveals Early Predictive and Pathogenic Signatures. Cell. 2020;182(5):1311-27.e14.","journal-title":"Cell"},{"key":"2899_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101367","volume":"54","author":"S Liu","year":"2021","unstructured":"Liu S, Gui Y, Wang MS, Zhang L, Xu T, Pan Y, et al. Serum integrative omics reveals the landscape of human diabetic kidney disease. Mol Metab. 2021;54: 101367.","journal-title":"Mol Metab"},{"issue":"12","key":"2899_CR15","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1016\/j.ophtha.2024.07.004","volume":"131","author":"S Yang","year":"2024","unstructured":"Yang S, Liu R, Xin Z, Zhu Z, Chu J, Zhong P, et al. Plasma metabolomics identifies key metabolites and improves prediction of diabetic retinopathy: development and validation across multinational cohorts. Ophthalmology. 2024;131(12):1436\u201346.","journal-title":"Ophthalmology"},{"issue":"4","key":"2899_CR16","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1002\/med.21883","volume":"42","author":"PR Pereira","year":"2022","unstructured":"Pereira PR, Carrageta DF, Oliveira PF, Rodrigues A, Alves MG, Monteiro MP. Metabolomics as a tool for the early diagnosis and prognosis of diabetic kidney disease. Med Res Rev. 2022;42(4):1518\u201344.","journal-title":"Med Res Rev"},{"key":"2899_CR17","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.lfs.2018.09.035","volume":"212","author":"N Wang","year":"2018","unstructured":"Wang N, Zhu F, Chen L, Chen K. Proteomics, metabolomics and metagenomics for type 2 diabetes and its complications. Life Sci. 2018;212:194\u2013202.","journal-title":"Life Sci"},{"issue":"2","key":"2899_CR18","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1161\/CIRCULATIONAHA.115.018585","volume":"133","author":"D Mozaffarian","year":"2016","unstructured":"Mozaffarian D. Dietary and policy priorities for cardiovascular disease, diabetes, and obesity: a comprehensive review. Circulation. 2016;133(2):187\u2013225.","journal-title":"Circulation"},{"issue":"11","key":"2899_CR19","doi-asserted-by":"publisher","first-page":"2309","DOI":"10.1038\/s41591-022-01980-3","volume":"28","author":"T Buergel","year":"2022","unstructured":"Buergel T, Steinfeldt J, Ruyoga G, Pietzner M, Bizzarri D, Vojinovic D, et al. Metabolomic profiles predict individual multidisease outcomes. Nat Med. 2022;28(11):2309\u201320.","journal-title":"Nat Med"},{"issue":"1","key":"2899_CR20","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1038\/s41467-023-36231-7","volume":"14","author":"H Julkunen","year":"2023","unstructured":"Julkunen H, Cicho\u0144ska A, Tiainen M, Koskela H, Nybo K, M\u00e4kel\u00e4 V, et al. Atlas of plasma NMR biomarkers for health and disease in 118,461 individuals from the UK Biobank. Nat Commun. 2023;14(1):604.","journal-title":"Nat Commun"},{"issue":"8","key":"2899_CR21","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41588-021-00892-1","volume":"53","author":"AR Barton","year":"2021","unstructured":"Barton AR, Sherman MA, Mukamel RE, Loh PR. Whole-exome imputation within UK Biobank powers rare coding variant association and fine-mapping analyses. Nat Genet. 2021;53(8):1260\u20139.","journal-title":"Nat Genet"},{"issue":"11","key":"2899_CR22","doi-asserted-by":"publisher","first-page":"1880","DOI":"10.1002\/sim.6835","volume":"35","author":"S Burgess","year":"2016","unstructured":"Burgess S, Dudbridge F, Thompson SG. Combining information on multiple instrumental variables in Mendelian randomization: comparison of allele score and summarized data methods. Stat Med. 2016;35(11):1880\u2013906.","journal-title":"Stat Med"},{"issue":"1","key":"2899_CR23","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s10020-021-00394-0","volume":"27","author":"M De Spiegeleer","year":"2021","unstructured":"De Spiegeleer M, De Paepe E, Van Meulebroek L, Gies I, De Schepper J, Vanhaecke L. Paediatric obesity: a systematic review and pathway mapping of metabolic alterations underlying early disease processes. Mol Med. 2021;27(1):145.","journal-title":"Mol Med"},{"key":"2899_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.118127","volume":"257","author":"OS Michael","year":"2020","unstructured":"Michael OS, Dibia CL, Soetan OA, Adeyanju OA, Oyewole AL, Badmus OO, et al. Sodium acetate prevents nicotine-induced cardiorenal dysmetabolism through uric acid\/creatine kinase-dependent pathway. Life Sci. 2020;257: 118127.","journal-title":"Life Sci"},{"issue":"3","key":"2899_CR25","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1038\/s42255-021-00369-9","volume":"3","author":"JG Okun","year":"2021","unstructured":"Okun JG, Rusu PM, Chan AY, Wu Y, Yap YW, Sharkie T, et al. Liver alanine catabolism promotes skeletal muscle atrophy and hyperglycaemia in type 2 diabetes. Nat Metab. 2021;3(3):394\u2013409.","journal-title":"Nat Metab"},{"issue":"3","key":"2899_CR26","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1111\/dom.15395","volume":"26","author":"KS Lee","year":"2024","unstructured":"Lee KS, Lee YH, Lee SG. Alanine to glycine ratio is a novel predictive biomarker for type 2 diabetes mellitus. Diabetes Obes Metab. 2024;26(3):980\u20138.","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2899_CR27","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1161\/CIRCULATIONAHA.123.065251","volume":"148","author":"JL Januzzi","year":"2023","unstructured":"Januzzi JL, Mohebi R, Liu Y, Sattar N, Heerspink HJL, Tefera E, et al. Cardiorenal biomarkers, canagliflozin, and outcomes in diabetic kidney disease: the CREDENCE trial. Circulation. 2023;148(8):651\u201360.","journal-title":"Circulation"},{"issue":"11","key":"2899_CR28","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.032626","volume":"13","author":"X Zhang","year":"2024","unstructured":"Zhang X, Zhao S, Huang Y, Ma M, Li B, Li C, et al. Diabetes-related macrovascular complications are associated with an increased risk of diabetic microvascular complications: a prospective study of 1518 patients with type 1 diabetes and 20 802 patients with type 2 diabetes in the UK Biobank. J Am Heart Assoc. 2024;13(11): e032626.","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"2899_CR29","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1186\/s10020-024-00845-4","volume":"30","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhang M, Zeng L, Lai Y, Wu S, Su X. Wogonin upregulates SOCS3 to alleviate the injury in diabetic nephropathy by inhibiting TLR4-mediated JAK\/STAT\/AIM2 signaling pathway. Mol Med. 2024;30(1):78.","journal-title":"Mol Med"},{"issue":"1","key":"2899_CR30","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1038\/s41392-023-01400-z","volume":"8","author":"Y Li","year":"2023","unstructured":"Li Y, Liu Y, Liu S, Gao M, Wang W, Chen K, et al. Diabetic vascular diseases: molecular mechanisms and therapeutic strategies. Signal Transduct Target Ther. 2023;8(1):152.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2899_CR31","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/0022-510X(94)90345-X","volume":"121","author":"N Patel","year":"1994","unstructured":"Patel N, Llewelyn J, Wright D, Thomas P. Glucose and leucine uptake by rat dorsal root ganglia is not insulin sensitive. J Neurol Sci. 1994;121(2):159\u201362.","journal-title":"J Neurol Sci"},{"issue":"1","key":"2899_CR32","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/nrn2294","volume":"9","author":"DR Tomlinson","year":"2008","unstructured":"Tomlinson DR, Gardiner NJ. Glucose neurotoxicity. Nat Rev Neurosci. 2008;9(1):36\u201345.","journal-title":"Nat Rev Neurosci"},{"key":"2899_CR33","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2112561118","author":"SA Mills","year":"2021","unstructured":"Mills SA, Jobling AI, Dixon MA, Bui BV, Vessey KA, Phipps JA, et al. Fractalkine-induced microglial vasoregulation occurs within the retina and is altered early in diabetic retinopathy. Proc Natl Acad Sci U S A. 2021. https:\/\/doi.org\/10.1073\/pnas.2112561118.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2899_CR34","doi-asserted-by":"publisher","first-page":"1780","DOI":"10.1016\/j.jacc.2023.02.050","volume":"81","author":"TC Gilliland","year":"2023","unstructured":"Gilliland TC, Liu Y, Mohebi R, Miksenas H, Haidermota S, Wong M, et al. Lipoprotein(a), oxidized phospholipids, and coronary artery disease severity and outcomes. J Am Coll Cardiol. 2023;81(18):1780\u201392.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"2899_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1093\/cvr\/cvy136","volume":"115","author":"C Yeang","year":"2019","unstructured":"Yeang C, Hasanally D, Que X, Hung MY, Stamenkovic A, Chan D, et al. Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids. Cardiovasc Res. 2019;115(1):179\u201389.","journal-title":"Cardiovasc Res"},{"key":"2899_CR36","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.metabol.2019.04.001","volume":"95","author":"Y Zeng","year":"2019","unstructured":"Zeng Y, Mtintsilana A, Goedecke JH, Micklesfield LK, Olsson T, Chorell E. Alterations in the metabolism of phospholipids, bile acids and branched-chain amino acids predicts development of type 2 diabetes in black South African women: a prospective cohort study. Metabolism. 2019;95:57\u201364.","journal-title":"Metabolism"},{"issue":"1","key":"2899_CR37","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1186\/s12933-024-02506-6","volume":"23","author":"P Rostoff","year":"2024","unstructured":"Rostoff P, Drwi\u0142a-Stec D, Majda A, St\u0119pie\u0144 K, Nessler J, Gajos G. Lipophilic index of serum phospholipids in patients with type 2 diabetes and atherosclerotic cardiovascular disease: links with metabolic control, vascular inflammation and platelet activation. Cardiovasc Diabetol. 2024;23(1):409.","journal-title":"Cardiovasc Diabetol"},{"issue":"4","key":"2899_CR38","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S2213-8587(13)70199-2","volume":"2","author":"E Selvin","year":"2014","unstructured":"Selvin E, Rawlings AM, Grams M, Klein R, Sharrett AR, Steffes M, et al. Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study. Lancet Diabetes Endocrinol. 2014;2(4):279\u201388.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2899_CR39","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12933-015-0219-y","volume":"14","author":"HJ Yoon","year":"2015","unstructured":"Yoon HJ, Lee YH, Kim SR, Rim TH, Lee EY, Kang ES, et al. Glycated albumin and the risk of micro- and macrovascular complications in subjects with type 1 diabetes. Cardiovasc Diabetol. 2015;14:53.","journal-title":"Cardiovasc Diabetol"},{"key":"2899_CR40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjdrc-2019-000877","author":"HH Luo","year":"2020","unstructured":"Luo HH, Li J, Feng XF, Sun XY, Li J, Yang X, et al. Plasma phenylalanine and tyrosine and their interactions with diabetic nephropathy for risk of diabetic retinopathy in type 2 diabetes. BMJ Open Diabetes Res Care. 2020. https:\/\/doi.org\/10.1136\/bmjdrc-2019-000877.","journal-title":"BMJ Open Diabetes Res Care"},{"issue":"7","key":"2899_CR41","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.1007\/s00125-018-4619-x","volume":"61","author":"P Welsh","year":"2018","unstructured":"Welsh P, Rankin N, Li Q, Mark PB, W\u00fcrtz P, Ala-Korpela M, et al. Circulating amino acids and the risk of macrovascular, microvascular and mortality outcomes in individuals with type 2 diabetes: results from the ADVANCE trial. Diabetologia. 2018;61(7):1581\u201391.","journal-title":"Diabetologia"},{"issue":"6 Suppl 1","key":"2899_CR42","doi-asserted-by":"publisher","first-page":"1539S","DOI":"10.1093\/jn\/137.6.1539S","volume":"137","author":"JD Fernstrom","year":"2007","unstructured":"Fernstrom JD, Fernstrom MH. Tyrosine, phenylalanine, and catecholamine synthesis and function in the brain. J Nutr. 2007;137(6 Suppl 1):1539S-S1547.","journal-title":"J Nutr"},{"issue":"6 Suppl 1","key":"2899_CR43","doi-asserted-by":"publisher","first-page":"1586S","DOI":"10.1093\/jn\/137.6.1586S","volume":"137","author":"JD Kopple","year":"2007","unstructured":"Kopple JD. Phenylalanine and tyrosine metabolism in chronic kidney failure. J Nutr. 2007;137(6 Suppl 1):1586S-S1590.","journal-title":"J Nutr"},{"issue":"4","key":"2899_CR44","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1161\/CIRCRESAHA.115.306246","volume":"118","author":"MG Sorci-Thomas","year":"2016","unstructured":"Sorci-Thomas MG, Thomas MJ. Microdomains, inflammation, and atherosclerosis. Circ Res. 2016;118(4):679\u201391.","journal-title":"Circ Res"},{"issue":"2","key":"2899_CR45","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1194\/jlr.R050252","volume":"56","author":"K \u00d6\u00f6rni","year":"2015","unstructured":"\u00d6\u00f6rni K, Rajam\u00e4ki K, Nguyen SD, L\u00e4hdesm\u00e4ki K, Plihtari R, Lee-Rueckert M, et al. Acidification of the intimal fluid: the perfect storm for atherogenesis. J Lipid Res. 2015;56(2):203\u201314.","journal-title":"J Lipid Res"},{"issue":"3","key":"2899_CR46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.diabres.2005.03.032","volume":"70","author":"MJ Jacobs","year":"2005","unstructured":"Jacobs MJ, Kleisli T, Pio JR, Malik S, L\u2019Italien GJ, Chen RS, et al. Prevalence and control of dyslipidemia among persons with diabetes in the United States. Diabetes Res Clin Pract. 2005;70(3):263\u20139.","journal-title":"Diabetes Res Clin Pract"},{"issue":"12","key":"2899_CR47","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1161\/01.ATV.19.12.2981","volume":"19","author":"JL Dixon","year":"1999","unstructured":"Dixon JL, Stoops JD, Parker JL, Laughlin MH, Weisman GA, Sturek M. Dyslipidemia and vascular dysfunction in diabetic pigs fed an atherogenic diet. Arterioscler Thromb Vasc Biol. 1999;19(12):2981\u201392.","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"12","key":"2899_CR48","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1161\/01.CIR.0000091257.27563.32","volume":"108","author":"MA Creager","year":"2003","unstructured":"Creager MA, L\u00fcscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108(12):1527\u201332.","journal-title":"Circulation"},{"issue":"43","key":"2899_CR49","doi-asserted-by":"publisher","first-page":"4528","DOI":"10.1093\/eurheartj\/ehac448","volume":"43","author":"X Zhou","year":"2022","unstructured":"Zhou X, Yu L, Zhao Y, Ge J. Panvascular medicine: an emerging discipline focusing on atherosclerotic diseases. Eur Heart J. 2022;43(43):4528\u201331.","journal-title":"Eur Heart J"},{"issue":"10","key":"2899_CR50","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/S2213-8587(17)30221-8","volume":"5","author":"S Basu","year":"2017","unstructured":"Basu S, Sussman JB, Berkowitz SA, Hayward RA, Yudkin JS. Development and validation of risk equations for complications of type 2 diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes Endocrinol. 2017;5(10):788\u201398.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"2899_CR51","doi-asserted-by":"publisher","first-page":"1925","DOI":"10.1007\/s00125-013-2940-y","volume":"56","author":"AJ Hayes","year":"2013","unstructured":"Hayes AJ, Leal J, Gray AM, Holman RR, Clarke PM. UKPDS outcomes model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82. Diabetologia. 2013;56(9):1925\u201333.","journal-title":"Diabetologia"},{"issue":"5","key":"2899_CR52","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2337\/dc12-0958","volume":"36","author":"S Tanaka","year":"2013","unstructured":"Tanaka S, Tanaka S, Iimuro S, Yamashita H, Katayama S, Akanuma Y, et al. Predicting macro- and microvascular complications in type 2 diabetes: the Japan Diabetes Complications Study\/the Japanese Elderly Diabetes Intervention Trial risk engine. Diabetes Care. 2013;36(5):1193\u20139.","journal-title":"Diabetes Care"},{"issue":"2","key":"2899_CR53","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1177\/1932296817706375","volume":"12","author":"A Dagliati","year":"2018","unstructured":"Dagliati A, Marini S, Sacchi L, Cogni G, Teliti M, Tibollo V, et al. Machine learning methods to predict diabetes complications. J Diabetes Sci Technol. 2018;12(2):295\u2013302.","journal-title":"J Diabetes Sci Technol"},{"issue":"9","key":"2899_CR54","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1093\/aje\/kwx016","volume":"186","author":"P W\u00fcrtz","year":"2017","unstructured":"W\u00fcrtz P, Kangas AJ, Soininen P, Lawlor DA, Davey Smith G, Ala-Korpela M. Quantitative serum nuclear magnetic resonance metabolomics in large-scale epidemiology: a primer on -omic technologies. Am J Epidemiol. 2017;186(9):1084\u201396.","journal-title":"Am J Epidemiol"}],"container-title":["Cardiovascular Diabetology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12933-025-02899-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12933-025-02899-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T01:47:34Z","timestamp":1757468854000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiab.biomedcentral.com\/articles\/10.1186\/s12933-025-02899-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,18]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2899"],"URL":"https:\/\/doi.org\/10.1186\/s12933-025-02899-y","relation":{},"ISSN":["1475-2840"],"issn-type":[{"value":"1475-2840","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,18]]},"assertion":[{"value":"27 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"UK Biobank obtained ethical approval from the North West Multi-Centre Research Ethics Committee to collect and utilize the data. The FinnGen Biobank study was likewise approved by the Coordinating Ethics Committee of the Helsinki and Uusimaa Hospital District. All participants provided written informed consent. Furthermore, since the data was publicly available and deidentified, institutional review board approval was waived for this analysis.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no financial or other conflicts of interest concerning this study. The funders had no role in the study design or implementation; data collection, management, analysis, or interpretation; manuscript preparation, review, or approval; or the decision to submit the manuscript for publication. The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"341"}}